BACKGROUND: Subcutaneous IFNbeta-1b (Betaferon) is an established immunomodulatory treatment for relapsing remitting MS and active secondary progressive multiple sclerosis (SPMS). It modulates cytokine and adhesion molecule expression but long term in vivo effects of IFNbeta-1b on the immune system are not known in multiple sclerosis. OBJECTIVE: To address the effects of IFNbeta-1b on serum levels for soluble adhesion molecules and cytokine receptors from MS patients. METHODS: Serial blood samples were obtained from 40 patients of the frequent MRI subgroup (20 patients each from the placebo and the IFNbeta-1b treatment group), participating in the European multi-center clinical trial with IFNbeta-1b for secondary progressive MS, at regular intervals for up to 36 months. Soluble adhesion molecules (sVCAM, sICAM-1, sL-Selectin) as well as TNF-receptor I and II were analysed in the serum of patients by enzyme linked immunosorbent assays (ELISAs). Monthly brain MRI was performed in 34 of these patients (16 patients from the placebo and 18 from the IFNbeta-1b group) during months 1-6 and 19-24 to monitor disease activity as assessed by newly occurring gadolinium (Gd) enhancing lesions. RESULTS: An early and significant increase in sVCAM and sTNF-RII serum levels was detected in 16 out of 20 patients (80 %) treated with subcutaneous IFNbeta-1b already at month 1 but was absent in all but one patient during placebo treatment (p < 0.01). Raised sVCAM and TNF RII serum levels during months 1-6 inversely correlated with less MRI activity in the 19-24 months treatment interval in the IFNa-1b treatment group ( p = 0.0093 for TNF-RII; p = 0.047 for VCAM). CONCLUSIONS: sVCAM and sTNF RII levels in the serum of SPMS patients are increased during IFNbeta-1b therapy and may at least in part explain some of the treatment effects, like reduced immune cell transmigration.
BACKGROUND: Subcutaneous IFNbeta-1b (Betaferon) is an established immunomodulatory treatment for relapsing remitting MS and active secondary progressive multiple sclerosis (SPMS). It modulates cytokine and adhesion molecule expression but long term in vivo effects of IFNbeta-1b on the immune system are not known in multiple sclerosis. OBJECTIVE: To address the effects of IFNbeta-1b on serum levels for soluble adhesion molecules and cytokine receptors from MS patients. METHODS: Serial blood samples were obtained from 40 patients of the frequent MRI subgroup (20 patients each from the placebo and the IFNbeta-1b treatment group), participating in the European multi-center clinical trial with IFNbeta-1b for secondary progressive MS, at regular intervals for up to 36 months. Soluble adhesion molecules (sVCAM, sICAM-1, sL-Selectin) as well as TNF-receptor I and II were analysed in the serum of patients by enzyme linked immunosorbent assays (ELISAs). Monthly brain MRI was performed in 34 of these patients (16 patients from the placebo and 18 from the IFNbeta-1b group) during months 1-6 and 19-24 to monitor disease activity as assessed by newly occurring gadolinium (Gd) enhancing lesions. RESULTS: An early and significant increase in sVCAM and sTNF-RII serum levels was detected in 16 out of 20 patients (80 %) treated with subcutaneous IFNbeta-1b already at month 1 but was absent in all but one patient during placebo treatment (p < 0.01). Raised sVCAM and TNF RII serum levels during months 1-6 inversely correlated with less MRI activity in the 19-24 months treatment interval in the IFNa-1b treatment group ( p = 0.0093 for TNF-RII; p = 0.047 for VCAM). CONCLUSIONS: sVCAM and sTNF RII levels in the serum of SPMS patients are increased during IFNbeta-1b therapy and may at least in part explain some of the treatment effects, like reduced immune cell transmigration.
Authors: M H Rep; H M Schrijver; T van Lopik; R Q Hintzen; M T Roos; H J Adèr; C H Polman; R A van Lier Journal: J Neuroimmunol Date: 1999-04-01 Impact factor: 3.478
Authors: K P Wandinger; C S Stürzebecher; B Bielekova; G Detore; A Rosenwald; L M Staudt; H F McFarland; R Martin Journal: Ann Neurol Date: 2001-09 Impact factor: 10.422
Authors: Sarah Floris; Sigrid R Ruuls; Anne Wierinckx; Susanne M A van der Pol; Ed Döpp; Peter H van der Meide; Christine D Dijkstra; Helga E De Vries Journal: J Neuroimmunol Date: 2002-06 Impact factor: 3.478
Authors: H P Hartung; K Reiners; J J Archelos; M Michels; P Seeldrayers; F Heidenreich; K W Pflughaupt; K V Toyka Journal: Ann Neurol Date: 1995-08 Impact factor: 10.422
Authors: Klaus-Peter Wandinger; Jan D Lünemann; Oliver Wengert; Judith Bellmann-Strobl; Orhan Aktas; Alexandra Weber; Eva Grundström; Stefan Ehrlich; Klaus-D Wernecke; Hans-Dieter Volk; Frauke Zipp Journal: Lancet Date: 2003-06-14 Impact factor: 79.321
Authors: Michael Auer; Angelika Bauer; Antonia Oftring; Dagmar Rudzki; Harald Hegen; Gabriel Bsteh; Franziska Di Pauli; Klaus Berek; Anne Zinganell; Thomas Berger; Markus Reindl; Florian Deisenhammer Journal: CNS Drugs Date: 2022-09-29 Impact factor: 6.497
Authors: Manuel Comabella; E Julià; M Tintoré; L Brieva; N Téllez; J Río; C López; A Rovira; X Montalban Journal: J Neurol Date: 2008-05-20 Impact factor: 4.849
Authors: Axel Haarmann; Eva Nowak; Annika Deiß; Susanne van der Pol; Camelia-Maria Monoranu; Gijs Kooij; Nora Müller; Paul van der Valk; Guido Stoll; Helga E de Vries; Friederike Berberich-Siebelt; Mathias Buttmann Journal: Acta Neuropathol Date: 2015-03-27 Impact factor: 17.088